Dublin, Aug. 16, 2017 -- The "R&D and Business Tracker for Bispecific Antibodies" newsletter has been added to Research and Markets' offering.
This information service about Bispecific Antibodies delivers 12 monthly update reports in pdf format by e-mail straight to your desk and provides online access to the author's R&D database for the subject field of the service during the one-year subscription period. Credentials to access the online database will be sent by e-mail within 24 hours after purchase.
This product consists of:
- 12 monthly update reports in pdf format delivered by e-mail
- online access to Bispecific Antibody R&D database during the 1-year subscription period
The R&D and Business Tracker for Bispecific Antibodies covers;
- T-Cell redirecting bispecific cancer antibodies
- NK cell redirecting bispecific cancer antibodies
- Bispecific immuno-oncology antibodies
- Bispecific tumor antigens targeted cancer antibodies
- Bispecific antibodies for inflammatory & autoimmune diseases
- Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases
The monthly update report about Bispecific Antibodies contains:
R&D and Technology Tracker
- Pipeline changes
- Regulatory news
- Technology validations
Business Tracker for:
- Company updates
- Collaboration
- Licensing
- Merger & acquisitions
- Financing
Clinical Trial Tracker
Scientific Publication Tracker
Featured Bispecific Antibody or Technology Profile
Featured Company Profile
Featured Target or Technology Pipeline
For more information about this newsletter visit https://www.researchandmarkets.com/research/6mq6rw/randd_and
CONTACT: Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Oncology Drugs
